A Randomized, Open-label, Parallel-controlled Clinical Study of Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency
There is a high incidence of women suffering from Primary Ovarian Insufficiency (POI). So far, there was no treatment sufficient enough to cure POI. Cell therapy is a rapidly developing field and have shown immense promise in the treatment of ovarian dysfunction. In this study, the investigator will evaluate the safety of human Amniotic mesenchymal stem cells (hA-MSCs) therapy in women suffering from POI.
• The intention of pregnant women aged \>= 20 and \< 40, with normal karyotype;
• Oligo/amenorrhea for at least 4 months;
• Elevated FSH level \>25 IU/l on two occasions \>4 weeks apart;
• Without a history of stem cell therapy and no growth hormone and/or estrogen and progesterone therapy within the previous 3 months;
• Voluntary participation in the study with signed informed consent;